Dr. Philippe E. Spiess, MD

Dr. Spiess practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Spiess' NPI, 1326157082, was assigned on August 29, 2006. Dr. Spiess graduated from University of Toronto Faculty of Medicine in 1999. Dr. Spiess holds Florida license ME99232.

Dr. Spiess' primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Spiess' primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Spiess is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Spiess to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spiess practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Spiess' primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Spiess is board certified in urology by the American Board of Urology. Dmand AI has Dr. Spiess' licenses on file in 2 states: Florida and Texas.

Dmand AI lists bladder removal, enlarged prostate transurethral surgery (TURP), kidney cysts, kidney removal surgery, urinary endoscopy and urine flow blockage among the conditions Dr. Spiess treats.

CMS data shows 503 Medicare services from Dr. Spiess across 12 procedure codes in 2024, for 312 Medicare patients. Medicare paid $53,635 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 312 Medicare patients who saw Dr. Spiess in 2024. The largest group is 75 to 84, with 140 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Spiess' median patient age at 71, with 31% women.

In 2024, Dr. Spiess wrote 306 Medicare Part D claims for 167 patients. 78% of them were for generic drugs. CMS names the drug for 266 of them, across 2 drugs with 11 or more claims each, at $690 in total drug cost. In 2023, CMS named 304 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Spiess for performance year 2024, reported as part of a group. Dr. Spiess accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Spiess as offering telehealth.

Hernia repair - groin (open): 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 478 papers to Dr. Spiess, published from 2007 to 2025. 2023 was the busiest year, with 42. The most frequent topics are Penile Neoplasms, Urinary Bladder Neoplasms and Lymph Node Excision. Dr. Spiess has published most often in Urol Oncol. Dr. Spiess' most frequent co-authors are Wade J. Sexton, MD, Jad Chahoud, MD and Julio M. Pow-Sang, MD.

Dmand AI links Dr. Spiess to 4 clinical trials. Conditions studied include Carcinoma, Transitional Cell, Non-Muscle Invasive Bladder Neoplasms and Prostatic Neoplasms. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 3.

CMS Open Payments shows 66 general payments to Dr. Spiess from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 51% of the total. Prometheus Laboratories Inc. paid the most, $6,245. It also lists 1 research payment totaling $800 in 2017.

Dr. Spiess graduated from University of Toronto Faculty of Medicine in 1999.

Dr. Spiess is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. HMO plans come from the most carriers, 8. Check the plan with the practice before a visit.